ONTX · Onconova Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | $2.73M | $57.0K | - | $57.0K | $57.0K | $56.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $2.51M | - | $2.31M | $2.29M | $1.91M | - | $5.11M | $2.46M | $1.91M | - |
| SG&A | $2.03M | - | $1.74M | $1.69M | $2.75M | - | $3.48M | $1.98M | $3.36M | - |
| Total Operating Expenses | $6.95M | - | $4.05M | $3.98M | $5.26M | - | $8.59M | $123.41M | $5.27M | - |
| D&A | $44.0K | - | - | - | $1.0K | - | - | - | $4.0K | - |
| Operating Income | ($6.95M) | - | ($4.05M) | ($1.25M) | ($5.20M) | - | ($8.54M) | ($123.35M) | ($5.21M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($7.11M) | - | ($3.96M) | ($915.0K) | ($4.98M) | - | ($8.47M) | ($123.14M) | ($4.98M) | - |
| EPS - Basic | ($0.53) | - | ($0.34) | ($0.11) | $2.17 | - | ($8.81) | ($4.87) | ($0.24) | - |
| EPS - Diluted | ($0.53) | - | ($0.34) | ($0.11) | $2.09 | - | ($8.81) | ($4.87) | ($0.24) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.13M | $3.82M | $6.42M | $13.08M | $15.94M | $21.34M | $5.41M | $16.89M | $16.39M | $20.56M |
| Accounts Receivable | $1.69M | $3.79M | $1.99M | $1.32M | $1.65M | $1.76M | $2.12M | $18.0K | $18.0K | $18.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $7.67M | $5.65M | $5.11M | $4.76M | $7.66M | $8.19M | $5.47M | $6.17M | $6.57M | $5.62M |
| Current Assets | $5.67M | $7.98M | $9.63M | $15.37M | $18.86M | $24.95M | $8.92M | $18.67M | $18.15M | $22.66M |
| Total Assets | $8.16M | $10.62M | $12.44M | $15.62M | $19.06M | $24.96M | $8.94M | $18.69M | $18.17M | $22.68M |
| Current Liabilities | $13.21M | $11.15M | $7.89M | $7.35M | $10.40M | $11.53M | $8.35M | $9.91M | $9.42M | $9.22M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $13.47M | $11.25M | $7.90M | $7.36M | $13.06M | $56.59M | $10.97M | $12.59M | $12.16M | $12.01M |
| Stockholders' Equity | ($5.31M) | ($629.0K) | $4.54M | $8.26M | $6.00M | ($31.63M) | ($2.03M) | ($105.52M) | $6.01M | $10.67M |
| Retained Earnings | ($647.09M) | ($639.98M) | ($632.54M) | ($628.58M) | ($627.66M) | ($649.15M) | ($619.23M) | ($610.76M) | ($487.61M) | ($482.63M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.58M) | - | - | - | ($5.44M) | - | - | - | ($4.42M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $1.90M | - | - | - | $13.0K | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | -45.7% | -9128.1% | - | -14975.4% | -216400.0% | -9307.1% | - |
| EBITDA margin | - | - | - | - | -9126.3% | - | - | - | -9300.0% | - |
| Net margin | - | - | - | -33.5% | -8742.1% | - | -14868.4% | -216040.4% | -8898.2% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | 83.8% | 3354.4% | - | 8970.2% | 4308.8% | 3414.3% | - |
| SG&A / Revenue | - | - | - | 61.9% | 4831.6% | - | 6105.3% | 3468.4% | 5992.9% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -87.1% | - | -31.8% | -5.9% | -26.1% | - | -94.8% | -659.0% | -27.4% | - |
| Return on equity | 133.8% | - | -87.2% | -11.1% | -83.0% | - | 416.9% | 116.7% | -82.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.43 | 0.72 | 1.22 | 2.09 | 1.81 | 2.16 | 1.07 | 1.88 | 1.93 | 2.46 |
| Quick ratio | 0.43 | 0.72 | 1.22 | 2.09 | 1.81 | 2.16 | 1.07 | 1.88 | 1.93 | 2.46 |
| Cash ratio | 0.24 | 0.34 | 0.81 | 1.78 | 1.53 | 1.85 | 0.65 | 1.70 | 1.74 | 2.23 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -1.54 | -16.88 | 2.74 | 1.89 | 3.18 | -0.79 | -4.40 | -0.18 | 3.02 | 2.13 |
| Liabilities / Assets | 1.65 | 1.06 | 0.63 | 0.47 | 0.69 | 2.27 | 1.23 | 0.67 | 0.67 | 0.53 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | 0.17 | 0.00 | - | 0.01 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | 177d | 10591d | - | 13582d | 115d | 117d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | 4694.7% | 1.8% | - | 0.0% | 0.0% | 0.0% | - |
| Revenue CAGR (3y) | - | - | - | 263.3% | 0.6% | - | 0.0% | 0.0% | 0.0% | - |
| Revenue CAGR (5y) | - | - | - | 117.6% | 1.9% | - | - | - | -3.8% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -33.5% | - | 52.5% | 99.0% | 0.2% | - | -67.7% | -2575.7% | 15.1% | - |
| Net income growth (YoY) | -42.6% | - | 53.3% | 99.3% | 0.0% | - | -78.8% | -2797.5% | 13.7% | - |
| EPS growth (YoY) | - | - | 96.1% | 97.7% | - | - | -3730.4% | -2335.0% | 14.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | 98.0% | - | - | -0.2% | - | - | - | -73.7% | -62.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$2.79M totalSingle Reportable Segment$2.79M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Onconova Therapeutics against the 5 most active filers in the same SIC group.